Apellis Sees Prelim. Q4 Net Product Revenues Of $138M For SYFOVRE And EMPAVELI; Sees 2023 Product Revenues Of $366M For SYFOVRE And EMPAVELI
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals reported preliminary Q4 net product revenues of $138M for SYFOVRE and EMPAVELI and expects 2023 product revenues of $366M for the same products.
January 08, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals anticipates robust sales, with preliminary Q4 net product revenues at $138M and projected 2023 revenues of $366M for SYFOVRE and EMPAVELI.
The reported preliminary Q4 revenues and the positive outlook for 2023 suggest strong sales performance and growth potential for Apellis Pharmaceuticals. This financial update is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100